Thermo Fisher announces Q1 revenue increase

By The Science Advisory Board staff writers

April 30, 2021 -- Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were partially responsible for significant revenue growth in its first quarter of 2021.

In the company's first quarter (end-April 3), revenue grew 59% to $9.9 billion, an increase over $6.2 billion in revenues reported in the first quarter of 2020.

In addition, the company stated it had a strong start to the year in terms of product launches, with two new mass spectrometers hitting the market, as well as a new electron microscope, purification system, and an in-air surveillance solution for pathogens, including SARS-CoV-2.

The company announced after its first quarter end that it inked a deal to acquire PPD, a leading global provider of clinical research services, for $17.4 billion.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.